查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1495416

a-乙酰洋地黄辛市场：依纯度、依适应症分类 - 2024-2030 年全球预测

a-Acetyldigitoxin Market by Purity (Less than 95%, More than 95%), Indication (Atrial Fibrillation, Cancer Therapy, Congestive Heart Failure) - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年a-乙酰洋地黄毒市场规模为2,020万美元，2024年达2,114万美元，预计2030年将达2,808万美元，复合年增长率为4.81%。

α-乙酰洋地黄毒苷是一种强心配配糖体，源自紫毛洋地黄和毛毛地黄，玄参科的着名成员。其机制涉及抑制 Na+/K+-ATP 酶。这种抑制增加了细胞内的钠浓度。结果，连锁反应增加了心肌细胞内的细胞内钙浓度，最终增加了心肌收缩力。 A-乙酰洋地黄毒在医学领域用于治疗某些对其他药物无反应的心臟疾病，例如心房颤动、心房扑动，有时甚至心臟衰竭。其作用机转与洋地黄毒苷相似，但乙酰化，可能影响吸收、分布、代谢、排泄等药物动力学。由于其有效作用和狭窄的治疗窗，给药需要仔细监测。全球心臟病盛行率的上升和新治疗方法的引入对α-乙酰洋地黄毒市场的扩张做出了积极贡献。与α-乙酰洋地黄辛相关的潜在副作用和毒性限制了患者和医疗保健提供者的使用。开发中国家医疗保健基础设施的扩大以及更安全、更有效製剂的研发为α-乙酰洋地黄辛市场渗透提供了巨大的机会。

主要市场统计
基准年[2023] 2020万美元
预计年份 [2024] 2114万美元
预测年份 [2030] 2808万美元
复合年增长率（%） 4.81%

区域洞察

在美洲，在医疗保健进步的推动下，a-乙酰洋地黄毒市场正在经历适度成长，美国拥有强大的医疗保健系统、大量的研发投资和大型製药公司。由于医疗保健的改善和慢性心臟疾病患病率的上升，拉丁美洲提供了潜在的成长机会。由于医疗保健支出不断增加、人口老化以及心臟病患者数量迅速增加，亚太市场正在迅速扩张。中国和印度由于人口众多、医疗保健意识高以及医疗基础设施发达，在这一增长中处于领先地位。亚太地区因其低廉的生产成本以及面临的挑战（例如多元化的法规环境和专利复杂性）而吸引了全球製药公司。 EMEA（欧洲、中东和非洲）地区呈现出多样化的市场动态，其中欧洲由于患者意识的提高和有利的报销政策而拥有强大的影响力。由于经济发展、医疗保健投资不断增加以及心血管疾病负担日益加重，中东和非洲地区提供了新的市场机会。

FPNV定位矩阵

FPNV 定位矩阵对于评估 A-乙酰洋地黄毒市场供应商的市场定位至关重要。此矩阵提供了对供应商的全面评估，并检验了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对 α-乙酰洋地黄毒市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他关键指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

策略分析与建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对 A-乙酰洋地黄毒苷市场当前地位的全面评估使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 越来越多的老年人口易患心臟病，全球心臟病发生率不断上升
      • 医疗保健基础设施和製药创新的政府政策和资金
      • 提高对心臟病的认识和诊断
    • 抑制因素
      • 与α-乙酰洋地黄毒相关的潜在不良反应和毒性
    • 机会
      • 药物输送系统的技术进步提高了 a-乙酰洋地黄毒苷治疗的疗效和患者依从性
      • a-乙酰洋地黄毒苷在向精准医疗和个人化医疗保健规划过渡中的潜力
    • 任务
      • 药物意识和影响范围有限
  • 市场区隔分析
    • 纯度：越来越多地采用纯度为 95% 或更高的 α-乙酰洋地黄毒苷来治疗心房颤动和郁血性心臟衰竭严重
    • 适应症：由于心血管疾病盛行率上升，对 a-乙酰洋地黄辛的需求增加
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章 a-乙酰洋地黄毒苷市场纯度

  • 低于95%
  • 95%以上

第七章 A-乙酰洋地黄毒素市场（按适应症）

  • 心房颤动
  • 癌症治疗
  • 心臟衰竭性郁血性

第八章美洲A-乙酰洋地黄毒市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太A-乙酰洋地黄毒市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章 欧洲/中东/非洲a-乙酰洋地黄毒市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 远藤推出右兰索拉唑胶囊，这是 Dexilant 的非专利药
    • C2 PHARMA 地高辛在中国获得核准
    • 剪切机-Smith 推出盐酸氟奋乃静锭剂
  • 战略分析和建议

第12章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-950610B5BB62

[186 Pages Report] The a-Acetyldigitoxin Market size was estimated at USD 20.20 million in 2023 and expected to reach USD 21.14 million in 2024, at a CAGR 4.81% to reach USD 28.08 million by 2030.

a-Acetyldigitoxin operates as a cardiac glycoside, sourced from Digitalis purpurea and Digitalis lanata, notable members of the Scrophulariaceae family. The mechanism involves the inhibition of the Na+/K+-ATPase enzyme. Such inhibition leads to a rise in intracellular sodium levels. Consequently, a cascade reaction heightens intracellular calcium concentrations within cardiac myocytes, ultimately boosting cardiac contractility. a-Acetyldigitoxin is utilized in the medical field to treat certain heart conditions, such as atrial fibrillation, atrial flutter, and sometimes heart failure, that are not responsive to other medications. Its mechanism of action is similar to that of digitoxin, but it is acetylated, which may affect its pharmacokinetics, including absorption, distribution, metabolism, and excretion. Due to its potent effects and narrow therapeutic window, dosing a-Acetyldigitoxin requires careful monitoring. The rising global incidence of cardiac conditions, and the introduction of novel therapeutic approaches contribute positively to the expansion of a-Acetyldigitoxin market. Potential adverse effects and toxicity associated with a-Acetyldigitoxin restrain its usage among patients and healthcare providers. Expanding healthcare infrastructures in developing countries and ongoing research into safer, more effective formulations present significant opportunities for a-Acetyldigitoxin market penetration.

KEY MARKET STATISTICS
Base Year [2023] USD 20.20 million
Estimated Year [2024] USD 21.14 million
Forecast Year [2030] USD 28.08 million
CAGR (%) 4.81%

Regional Insights

In the Americas, the a-Acetyldigitoxin market is experiencing moderate growth, propelled by healthcare advancements, with the United States having a strong healthcare system, substantial R&D investments, and leading pharmaceutical entities. Latin America presents potential growth opportunities through improved healthcare accessibility and a rising prevalence of chronic heart diseases. The Asia Pacific a-Acetyldigitoxin market is rapidly expanding, driven by increased healthcare spending, an aging demographic, and a surge in heart disease cases. China and India are leading this growth due to their vast populations, enhanced healthcare awareness, and better healthcare infrastructures. The Asia Pacific region attracts global pharmaceutical firms due to lower production costs, despite facing challenges such as diverse regulatory environments and patent complexities. The EMEA region exhibits varied market dynamics, with Europe maintaining a significant market presence through advanced heightened patient awareness and favorable reimbursement policies. The Middle East and Africa offer emerging market opportunities backed by economic advancements, growing healthcare investments, and an escalating cardiovascular disease burden.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the a-Acetyldigitoxin Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing geriatric population vulnerable to heart diseases and the increasing global incidence of cardiac conditions
      • Governmental policies and funding in healthcare infrastructure and pharmaceutical innovation
      • Rising awareness and diagnostic rates of heart diseases
    • Market Restraints
      • Potential adverse effects and toxicity associated with a-Acetyldigitoxin
    • Market Opportunities
      • Technological advancements in drug delivery systems, improving the efficacy and patient compliance of a-Acetyldigitoxin treatments
      • Shift towards precision medicine and the potential for a-Acetyldigitoxin in personalized healthcare regimens
    • Market Challenges
      • Limited awareness and limited reachability of the drug
  • Market Segmentation Analysis
    • Purity: Increasing adoption of a-Acetyldigitoxin with over 95% purity treating critical conditions such as atrial fibrillation and congestive heart failure
    • Indication: Rising prevalence of cardiovascular diseases increasing demand for a-Acetyldigitoxin
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the a-Acetyldigitoxin Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the a-Acetyldigitoxin Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant

Endo International plc announced that its subordinate entity, Par Pharmaceutical, Inc., has initiated the distribution of the generic variant of Takeda's Dexilant, dexlansoprazole 30 mg capsules. This launch expands the existing product line to include both 30 mg and 60 mg delayed-release capsules, catering to a broader range of patient needs. [Published On: 2023-06-15]

C2 PHARMA Granted Approval for Digoxin in China

C2 PHARMA, a provider of ophthalmic and specialized active pharmaceutical ingredients (APIs), has the acceptance of a C-Drug Master Filing (DMF) for Digoxin by its production ally in Poland, Nobilus Ent. This critical milestone, reached after an arduous three-year endeavor disrupted by the Covid pandemic, authorizes the commercialization of both Digoxin and its micronized variant in China. These approvals extend to an array of drug product formulations, including oral and injectable versions. Extracted from the Digitalis lanata plant leaves, Digoxin stands as a pivotal cardiac glycoside in treating mild to moderate heart failure, marking a noteworthy advancement in global heart health management. This approval also enables the company to commercialize Digoxin in China. [Published On: 2023-06-14]

Upsher-Smith Launches Fluphenazine Hydrochloride Tablets

Upsher-Smith Laboratories, LLC announces the deployment of its Fluphenazine Hydrochloride Tablets, available in dosages of 1 mg, 2.5 mg, 5 mg, and 10 mg. Serving as a generic counterpart to the branded Prolixin, these tablets expand Upsher-Smith's portfolio, reinforcing its commitment to providing accessible mental health treatment options. [Published On: 2023-04-03]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the a-Acetyldigitoxin Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the a-Acetyldigitoxin Market, highlighting leading vendors and their innovative profiles. These include Biosynth Ltd, C-Squared Pharma S.a R.L., Cayman Chemical Company, Endo International plc, Medicapharma BV, Merck KGaA, Nordic Biosite, Pharmaoffer, Santa Cruz Biotechnology, Inc., Thermo Fisher Scientific Inc., and Tocris Bioscience.

Market Segmentation & Coverage

This research report categorizes the a-Acetyldigitoxin Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Purity
    • Less than 95%
    • More than 95%
  • Indication
    • Atrial Fibrillation
    • Cancer Therapy
    • Congestive Heart Failure
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population vulnerable to heart diseases and the increasing global incidence of cardiac conditions
      • 5.1.1.2. Governmental policies and funding in healthcare infrastructure and pharmaceutical innovation
      • 5.1.1.3. Rising awareness and diagnostic rates of heart diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Potential adverse effects and toxicity associated with a-Acetyldigitoxin
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in drug delivery systems, improving the efficacy and patient compliance of a-Acetyldigitoxin treatments
      • 5.1.3.2. Shift towards precision medicine and the potential for a-Acetyldigitoxin in personalized healthcare regimens
    • 5.1.4. Challenges
      • 5.1.4.1. Limited awareness and limited reachability of the drug
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Purity: Increasing adoption of a-Acetyldigitoxin with over 95% purity treating critical conditions such as atrial fibrillation and congestive heart failure
    • 5.2.2. Indication: Rising prevalence of cardiovascular diseases increasing demand for a-Acetyldigitoxin
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. a-Acetyldigitoxin Market, by Purity

  • 6.1. Introduction
  • 6.2. Less than 95%
  • 6.3. More than 95%

7. a-Acetyldigitoxin Market, by Indication

  • 7.1. Introduction
  • 7.2. Atrial Fibrillation
  • 7.3. Cancer Therapy
  • 7.4. Congestive Heart Failure

8. Americas a-Acetyldigitoxin Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific a-Acetyldigitoxin Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa a-Acetyldigitoxin Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. Endo Launches Dexlansoprazole Capsules, Generic Version of Dexilant
    • 11.3.2. C2 PHARMA Granted Approval for Digoxin in China
    • 11.3.3. Upsher-Smith Launches Fluphenazine Hydrochloride Tablets
  • 11.4. Strategy Analysis & Recommendation

12. Competitive Portfolio

  • 12.1. Key Company Profiles
  • 12.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. A-ACETYLDIGITOXIN MARKET RESEARCH PROCESS
  • FIGURE 2. A-ACETYLDIGITOXIN MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. A-ACETYLDIGITOXIN MARKET DYNAMICS
  • FIGURE 7. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 12. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 14. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. A-ACETYLDIGITOXIN MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 20. A-ACETYLDIGITOXIN MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. A-ACETYLDIGITOXIN MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY LESS THAN 95%, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY LESS THAN 95%, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY MORE THAN 95%, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY MORE THAN 95%, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CANCER THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL A-ACETYLDIGITOXIN MARKET SIZE, BY CONGESTIVE HEART FAILURE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 22. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 23. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 24. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 25. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 26. AMERICAS A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 27. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 28. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 29. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 30. ARGENTINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 31. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 32. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 33. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 34. BRAZIL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 35. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 36. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 37. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 38. CANADA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 39. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 40. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 41. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 42. MEXICO A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 43. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 44. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 45. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 46. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 47. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 48. UNITED STATES A-ACETYLDIGITOXIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 56. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 58. AUSTRALIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 59. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 60. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 61. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 62. CHINA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 63. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 64. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 65. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. INDIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 68. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 69. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 70. INDONESIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 71. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 72. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 73. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 74. JAPAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 75. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 76. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 77. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. MALAYSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 80. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 82. PHILIPPINES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 83. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 84. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 85. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 86. SINGAPORE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 88. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 90. SOUTH KOREA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 91. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 92. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 93. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 94. TAIWAN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 95. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 96. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 97. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. THAILAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 100. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 101. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 102. VIETNAM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 109. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 110. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 111. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 112. DENMARK A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 113. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 114. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 115. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 116. EGYPT A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 117. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 118. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 119. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 120. FINLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 121. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 122. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 123. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 124. FRANCE A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 125. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 126. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 127. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 128. GERMANY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 129. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 130. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 131. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 132. ISRAEL A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 133. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 134. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 135. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 136. ITALY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 138. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 140. NETHERLANDS A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 141. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 142. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 143. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 144. NIGERIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 145. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 146. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 147. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 148. NORWAY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 149. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 150. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 151. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. POLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 154. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 155. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 156. QATAR A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 157. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 158. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 159. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 160. RUSSIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 162. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SAUDI ARABIA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 166. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH AFRICA A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 169. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 170. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 171. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SPAIN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 174. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 175. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 176. SWEDEN A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 178. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 180. SWITZERLAND A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 182. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 183. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 184. TURKEY A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2018-2023 (USD MILLION)
  • TABLE 190. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY PURITY, 2024-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. UNITED KINGDOM A-ACETYLDIGITOXIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. A-ACETYLDIGITOXIN MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. A-ACETYLDIGITOXIN MARKET, FPNV POSITIONING MATRIX, 2023